The same practices, year after year: a national observational study of higher-risk antibiotic prescribing in English general practice, 2023-2026
Background: There is increasing antibiotic resistance in England. National targets have been set to increase the proportion of antibiotics prescribed in the lower risk Access category. The proportion of higher risk antibiotics within the Watch+Reserve category prescribed in each general practice is publicly available. It is unclear whether a high proportion of Watch+Reserve antibiotics in a practice is due to random variation, patient population or a persistent trend. Methods: Observational study using NHS open prescribing data from 5,791 general practices in England (26.0 million items, September 2025 to August 2026, and the two previous years). Watch+Reserve proportions were compared between practices using over-dispersion adjusted funnel plots with 99.8% control limits. Practices identified as outliers were tested using subsequent data. A quasi-binomial model was fitted adjusting for age, deprivation, practice size and 7 disease registers. Results: 117 practices exceeded the 99.8% control limit (approximately 6 expected by chance). 106 practices were included in a shortlist. Of those in the shortlist in 2024/25, 61% (95% CI 52-70%) exceeded the control limit in 2025/26 compared to 1.0% of all other practices. 36 practices were shortlisted in all 3 years. Adjusting for age, deprivation, practice size and disease registers explained 4.1% of variability. Following adjustment, 101 of 106 practices remained outliers. Overall, shortlisted practices did not prescribe more antibiotics than other practices (median 422 vs 438 items per 1,000 patients per year), but did prescribe fewer Access antibiotics and more Watch+Reserve antibiotics. 10% or fewer of excess Watch+Reserve antibiotics in England were prescribed in shortlisted practices. Conclusions: A small number of practices show persistently high prescribing of higher risk antibiotics, which cannot be explained by recorded need. This provides integrated care boards (ICBs) with a reliable list of practices to review. It was not possible to investigate penicillin allergy. To meet national Access targets, interventions will be needed in all practices, particularly reviewing the use of clarithromycin, co-amoxiclav and azithromycin.
Authors
- Agarwal Ashish
- Aashish Gill
Institutions
- University of Birmingham (GB)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-20
- DOI
- https://doi.org/10.64898/2026.11.18.26368426
- Primary Topic
- Antibiotic Use and Resistance
- Type
- preprint